External radiotherapy for prostatic cancers. 2022

R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
Département de radiothérapie, Centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France. Electronic address: r.de-crevoisier@rennes.unicancer.fr.

We present the update of the recommendations of the French society of oncological radiotherapy on external radiotherapy of prostate cancer. External radiotherapy is intended for all localized prostate cancers, and more recently for oligometastatic prostate cancers. The irradiation techniques are detailed. Intensity-modulated radiotherapy combined with prostate image-guided radiotherapy is the recommended technique. A total dose of 74 to 80Gy is recommended in case of standard fractionation (2Gy per fraction). Moderate hypofractionation (total dose of 60Gy at a rate of 3Gy per fraction over 4 weeks) in the prostate has become a standard of therapy. Simultaneous integrated boost techniques can be used to treat lymph node areas. Extreme hypofractionation (35 to 40Gy in five fractions) using stereotactic body radiotherapy can be considered a therapeutic option to treat exclusively the prostate. The postoperative irradiation technique, indicated mainly in case of biological recurrence and lymph node involvement, is detailed.

UI MeSH Term Description Entries
D008297 Male Males
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015182 Lymphatic Irradiation External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis. Lymphatic Radiation Therapy,Lymphoid Irradiation,Radiotherapy, Lymphatic,Irradiation, Lymphatic,Irradiation, Lymphoid,Lymphatic Radiotherapy,Radiation Therapy, Lymphatic,Therapy, Lymphatic Radiation,Irradiations, Lymphatic,Irradiations, Lymphoid,Lymphatic Irradiations,Lymphatic Radiation Therapies,Lymphatic Radiotherapies,Lymphoid Irradiations,Radiation Therapies, Lymphatic,Radiotherapies, Lymphatic,Therapies, Lymphatic Radiation
D016634 Radiosurgery A radiological stereotactic technique developed for cutting or destroying tissue by high doses of radiation in place of surgical incisions. It was originally developed for neurosurgery on structures in the brain and its use gradually spread to radiation surgery on extracranial structures as well. The usual rigid needles or probes of stereotactic surgery are replaced with beams of ionizing radiation directed toward a target so as to achieve local tissue destruction. Gamma Knife Radiosurgery,Linear Accelerator Radiosurgery,Stereotactic Body Radiotherapy,Stereotactic Radiosurgery,CyberKnife Radiosurgery,LINAC Radiosurgery,Radiosurgery, Gamma Knife,Radiosurgery, Linear Accelerator,Radiosurgery, Stereotactic,Stereotactic Radiation,Stereotactic Radiation Therapy,CyberKnife Radiosurgeries,Gamma Knife Radiosurgeries,LINAC Radiosurgeries,Linear Accelerator Radiosurgeries,Radiation Therapy, Stereotactic,Radiation, Stereotactic,Radiosurgery, CyberKnife,Radiosurgery, LINAC,Radiotherapy, Stereotactic Body,Stereotactic Body Radiotherapies,Stereotactic Radiation Therapies,Stereotactic Radiations,Stereotactic Radiosurgeries,Therapy, Stereotactic Radiation
D047368 Tumor Burden The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body. Tumor Load,Tumor Volume,Tumor Weight,Burden, Tumor,Load, Tumor,Loads, Tumor,Tumor Loads,Tumor Weights,Volume, Tumor,Weight, Tumor,Weights, Tumor

Related Publications

R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
July 1981, International journal of radiation oncology, biology, physics,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
May 1985, Cancer,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
June 1988, Hiroshima journal of medical sciences,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
April 2001, Urology,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
March 1993, The Journal of urology,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
January 1993, Rays,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
November 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
November 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
January 1993, Rays,
R de Crevoisier, and S Supiot, and G Créhange, and P Pommier, and I Latorzeff, and O Chapet, and D Pasquier, and P Blanchard, and U Schick, and V Marchesi, and P Sargos, and C Hennequin
May 1974, Urology,
Copied contents to your clipboard!